Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 6, 2013, Pages 1032-1042

  Enden, T ^a,b   Resch, S ^b   White, C ^b   Wik, H S ^a,c   Klow N E ^a,c   Sandset, P M ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Anticoagulation; Cost effectiveness analysis; Decision model; Post thrombotic syndrome; Thrombolytic therapy; Venous thrombosis

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CATHETER DIRECTED THROMBOLYSIS; CATHETER THROMBOSIS; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; FOLLOW UP; HOSPITAL COST; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFESPAN; OUTPATIENT DEPARTMENT; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TABLET; TREATMENT DURATION; UNCERTAINTY; VENOUS THROMBOEMBOLISM;

ANTICOAGULATION; COST-EFFECTIVENESS ANALYSIS; DECISION MODEL; POST-THROMBOTIC SYNDROME; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; CATHETERS; COST-BENEFIT ANALYSIS; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; PROBABILITY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; RISK; SENSITIVITY AND SPECIFICITY; THROMBOLYTIC THERAPY; VENOUS THROMBOSIS;

EID: 84878839954     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12184     Document Type: Article

References (57)

1. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
2. Prandoni P, Lensing AW, Prins MH, Frulla M, Marchiori A, Bernardi E, Tormene D, Mosena L, Pagnan A, Girolami A. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-56.
3. Brandjes DP, Büller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, ten Cate JW. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-62.
4. Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
5. Guanella R, Ducruet T, Johri M, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Ginsberg JS, Lamping DL, Shrier I, Kahn SR. Economic burden and cost determinants of deep vein thrombosis during two years following diagnosis: a prospective evaluation. J Thromb Haemost 2011; 9: 2397-405.
6. Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K. Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 1997; 126: 454-7.
7. Kahn SR, Hirsch A, Shrier I. Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162: 1144-8.
8. Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379: 31-8.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
10. Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen LO, Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM. Catheter-directed venous thrombolysis in acute iliofemoral vein thrombosis-the CaVenT Study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). Am Heart J 2007; 154: 808-14.
11. Villalta S, Bagatella P, Piccioli A, Lensing AW, Prins MH, Prandoni P. Assessment of validity and reproducibility of a clinical scale for the postthrombotic syndrome. Haemostasis 1994; 24 (Suppl. 1): 157.
12. Kahn SR, Partsch H, Vedantham S, Prandoni P, Kearon C. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost 2009; 7: 879-83.
13. de Jong PG, Coppens M, Middeldorp S. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term. Br J Haematol 2012; 158: 433-41.
14. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med 2011; 154: 1-11.
15. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007; 25: 3-6.
16. Zia E, Engstrom G, Svensson PJ, Norrving B, Pessah-Rasmussen H. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009; 40: 3567-73.
17. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001; 111: 130-9.
18. Forgie MA., Wells P. Duration of oral anticoagulation in first-episode idiopathic deep vein thrombosis: A Markov decision analysis. Thesis/Dissertation. University of Ottawa Canada, 2001.
19. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S, Bank I, van der Meer J, Hamulyák K, Prins MH. Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thromb Haemost 2004; 92: 1336-41.
20. MacLean S, Mulla S, Akl EA, Jankowski M, Vandvik PO, Ebrahim S, McLeod S, Bhatnagar N, Guyatt GH; American College of Chest Physicians. Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e1S-23S.
21. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, Bernardi E, Girolami B, Simioni P, Girolami A. The clinical course of deep vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-8.
22. Ghanima W, Kleven IW, Enden T, Rosales A, Wik HS, Pederstad L, Holme PA, Sandset PM. Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis. J Thromb Haemost 2011; 9: 1261-3.
23. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211: 39-49.
24. Carrier M, le Gal, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-89.
25. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900.
26. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167-76.
27. Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005; 294: 706-15.
28. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, Iotti M, Tormene D, Simioni P, Pagnan A. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1, 626 patients. Haematologica 2007; 92: 199-205.
29. Flinterman LE, van Hylckama Vlieg A, Cannegieter SC, Rosendaal FR. Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012; 9: e1001155.
30. Wittrup-Jensen KU, Lauridsen J, Gudex C, Pedersen KM. Generation of a Danish TTO value set for EQ-5D health states. Scand J Public Health 2009; 37: 459-66.
31. Michaels JA, Campbell WB, King BM, Macintyre J, Palfreyman SJ, Shackley P, Stevenson MD. A prospective randomised controlled trial and economic modelling of antimicrobial silver dressings versus non-adherent control dressings for venous leg ulcers: the VULCAN trial. Health Technol Assess 2009; 13: 1-114, iii.
32. Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol 2012; 88: 185-94.
33. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, Pashos CL, Cohen AT. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59-74.
34. Ramacciotti E, Gomes M, de Aguiar ET, Caiafa JS, de Moura LK, Araújo GR, Truzzi A, Dietrich-Neto F; CLE-PTS Investigators. A cost analysis of the treatment of patients with post-thrombotic syndrome in Brazil. Thromb Res 2006; 118: 699-704.
35. Fjaertoft H, Indredavik B, Magnussen J, Johnsen R. Early supported discharge for stroke patients improves clinical outcome. Does it also reduce use of health services and costs? One-year follow-up of a randomized controlled trial. Cerebrovasc Dis 2005; 19: 376-83.
36. Wisløff T, Selmer RM, Halvorsen S, Kristiansen IS. Norwegian Cardiovascular Disease Model (NorCaD) - a simulation model for estimating health benefits and cost consequences of cardiovascular interventions. [23]. 2008. The Norwegian Knowledge Centre for the Health Services, Oslo.
37. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year? Med Care 2008; 46: 343-5.
38. Schulman S. Getting intimate with the venous thrombus. J Thromb Haemost 2009; 7: 1266-7.
39. Vedantham S, Grassi CJ, Ferral H, Patel NH, Thorpe PE, Antonacci VP, Janne d'Othée BM, Hofmann LV, Cardella JF, Kundu S, Lewis CA, Schwartzberg MS, Min RJ, Sacks D; Technology Assessment Committee of the Society of Interventional Radiology. Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. J Vasc Interv Radiol 2006; 17: 417-34.
40. Hofmann LV, Kuo WT. Catheter-directed thrombolysis for acute DVT. Lancet 2012; 379: 3-4.
41. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori A, Bagatella P, Frulla M, Mosena L, Tormene D, Piccioli A, Simioni P, Girolami A. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.
42. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, Scannapieco G, Ambrosio GB, Pesavento R, Cuppini S, Quintavalla R, Agnelli G; AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150: 577-85.
43. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24: 209-14.
44. Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT study group. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost 2009; 7: 1268-75.
45. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22: 857-76.
46. Goeree R, He J, O'Reilly D, Tarride JE, Xie F, Lim M, Burke N. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. Clinicoecon Outcomes Res 2011; 3: 89-104.
47. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S-84S.
48. MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J. Economic burden of deep vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63: S5-15.
49. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005; 14: 1523-32.
50. Kahn SR, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Ginsberg JS. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6: 1105-12.
51. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
52. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
53. Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001; 32: 1425-9.
54. Dorman P, Dennis M, Sandercock P. Are the modified "simple questions" a valid and reliable measure of health related quality of life after stroke? United Kingdom Collaborators in the International Stroke Trial. J Neurol Neurosurg Psychiatry 2000; 69: 487-93.
55. Fjaertoft H, Indredavik B. Cost-estimates for stroke. Tidsskr Nor Laegeforen 2007; 127: 744-7.
56. Tan-Torres Edejer T. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. Geneva: World Health Organization, 2003.
57. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.